Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after colorectal cancer surgery in Chulabhorn hospital
Ontology highlight
ABSTRACT:
DISEASE(S): Patients With Colorectal Cancer Surgery In Chulabhorn Hopital,Vte Prevention, Vte Prophylaxis, Colorectal Cancer Surgery
PROVIDER: 94884 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Microarray and quantitative real-time PCR (qRT-PCR) results showed that the Caspase-1 expression was increased while miR-513c-5p level was decreased substantially in DVT patients, and there was significant negative correlation between miR-513c-5p and Caspase-1. Knockdown of miR-513c-5p could aggravate DVT formation by enhancing Caspase-1-mediated pyroptosis, while overexpression of miR-513c-5p could alleviate DVT formation via inhibiting Caspase-1 expression. we identified pyroptosis of PBMCs with elevated expression of Caspase-1 in DVT patients. miRNA microarray analysis revealed miR-513c-5p as the most significantly down-regulated miRNA in DVT and the receiver operating characteristic (ROC) analysis showed that miR-513c-5p level could sensitively discriminate DVT from healthy controls.
2022-04-27 | GSE173461 | GEO
Project description:Deep vein thrombosis (DVT) is a common clinical problem, but its cellular and molecular mechanisms remain incompletely understood. We performed single-cell RNA sequencing (scRNA-seq) on the vein wall of mouse inferior vena cava (IVC) ligation model of deep vein thrombosis (DVT), to analyze the transcriptomic changes in the vein wall during acute venous thrombosis.
2023-02-10 | GSE221978 | GEO
Project description:Interventions: Enoxaparin group Subcutaneous injection of enoxaparin 2000U twice daily (postoperative day 2 to discharge) Intermittent pneumatic compression (IPC) prophylaxis (after surgery to postoperative day 1)
Control group IPC prophylaxis alone (after surgery to postoperative day 1)
Primary outcome(s): Incidence of venos thromboembolism until postoperative day 28
Study Design: Parallel Randomized
| 2633931 | ecrin-mdr-crc
Project description:The chemoprophylaxis of deep vein thrombosis (DVT) with subcutaneous low-molecular-weight heparin (enoxaparin) in the postoperative period of elective surgeries is already well established in the literature and in clinical practice. However, the use of this medication can have a financial impact on the patient and the parenteral presentation itself is associated with pain at the application site, which can make it difficult for patients to adhere.
| 2711239 | ecrin-mdr-crc
Project description:Comparing the effect of unilateral ischemia-reperfusion injury (IRI) or sham operation (sIRI) with delayed contralateral nephrectomy (Nx) or sham operation (sNx) in mouse kidney. IRI was performed on day 0 and the contralateral kidney was removed on day 7. Mice were sacrificed on day 8. Four animals were selected from the sham IRI-sham Nx and sham IRI-Nx groups and six animals were selected from the IRI-sham Nx and IRI-Nx groups for miRNA microArray analysis on the base of their proinflammatory (TNF-α and IL-6 and CCL2) and immune system-related (Complement component 3) mRNA expression levels.
2020-09-01 | GSE157221 | GEO
Project description:Manuscript Title:
Co-targeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
Journal:
Journal of Clinical Investigation
Authors
Vivian Changying Jiang1, Yang Liu1, Junwei Lian1, Shengjian Huang1, Alexa Jordan1, Qingsong Cai1, Fangfang Yan3, Joseph Mitchell McIntosh1, Yijing Li1, Yuxuan Che1, Zhihong Chen1, Jovanny Vargas1, Maria Badillo1, JohnNelson Bigcal1, Heng-Huan Lee1, Wei Wang1, Yixin Yao1, Lei Nie1, Christopher Flowers1, and Michael Wang1, 2*
Abstract
Bruton’s tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We here report that MALT1 is one of the top overexpressed genes in ibrutinib-resistant MCL cells, while expression of CARD11, which is upstream of MALT1, is decreased. MALT1 genetic knockout or inhibition produced dramatic defects in MCL cell growth regardless of ibrutinib sensitivity. Conversely, CARD11 knockout cells showed anti-tumor effects only in ibrutinib-sensitive cells, suggesting that MALT1 overexpression could drive ibrutinib resistance via bypassing BTK-CARD11 signaling. Additionally, BTK knockdown and MALT1 knockout markedly impaired MCL tumor migration and dissemination, and MALT1 pharmacological inhibition decreased MCL cell viability, adhesion, and migration by suppressing NF-κB, PI3K-ATK-mTOR, and integrin signaling. Importantly, co-targeting MALT1 with safimaltib and BTK with pirtobrutinib induced potent anti-MCL activity in ibrutinib-resistant MCL cell lines and patient-derived xenografts. Therefore, we conclude that MALT1 overexpression associates with resistance to BTK inhibitors in MCL, targeting abnormal MALT1 activity could be a promising therapeutic strategy to overcome BTK inhibitor resistance, and co-targeting of MALT1 and BTK should improve MCL treatment efficacy and durability as well as patient outcomes.
Dataset description:
The bulk RNA-seq dataset was generated for the cell lines below and used for two major purposes:
1. DEG analysis and GSEA analysis comparing IBN-R and IBN-S cells
2. DEG analysis and GSEA analysis comparing MCL cells with/without MI-2 treatment.
sample Cell MI-2 Ibrutinib (IBN) Venetoclax (VEN) Used for IBN-R vs IBN-S comparison Used for MI-2 vs untreated (DMSO)
H9 Granta519 - R S yes
H21 Granta519 - R S yes
H33 Granta519 - R S yes
H10 Granta519-VEN-R - R R yes
H22 Granta519-VEN-R - R R yes
H34 Granta519-VEN-R - R R yes
H3 JeKo BTK KD_1 - R R yes yes
H15 JeKo BTK KD_1 - R R yes yes
H27 JeKo BTK KD_1 - R R yes yes
H5 JeKo BTK KD_2 - R R yes yes
H17 JeKo BTK KD_2 - R R yes yes
H29 JeKo BTK KD_2 - R R yes yes
H1 JeKo-1 - S R yes yes
H13 JeKo-1 - S R yes yes
H25 JeKo-1 - S R yes yes
H7 Mino - S S yes
H19 Mino - S S yes
H31 Mino - S S yes
H8 Mino-VEN-R - S R yes
H20 Mino-VEN-R - S R yes
H32 Mino-VEN-R - S R yes
H11 Rec-1 - S S yes
H23 Rec-1 - S S yes
H12 Rec-VEN-R - S S yes
H24 Rec-VEN-R - S R yes
H36 Rec-VEN-R - S R yes
H35 Rec-1 -- S R yes
H4 JeKo BTK KD_1 + MI-2 + yes
H16 JeKo BTK KD_1 + MI-2 + yes
H28 JeKo BTK KD_1 + MI-2 + yes
H6 JeKo BTK KD_2 + MI-2 + yes
H18 JeKo BTK KD_2 + MI-2 + yes
H30 JeKo BTK KD_2 + MI-2 + yes
H2 JeKo-1 + MI-2 + yes
H14 JeKo-1 + MI-2 + yes
H26 JeKo-1 + MI-2 + yes
| EGAD00001009771 | EGA
Project description:As current bovine pregnancy detection methods are not reliable until at least day 28 post artificial insemination (AI), commercial interest exists for the discovery of novel biomarkers of pregnancy which could reliably detect pregnancy status at or before day 21 of pregnancy. This would allow producers the opportunity to rebreed at the next oestrus event. Therefore, the objective of the present study was to use liquid chromatography tandem mass spectrometry (LC-MS/MS) to perform a global, label-free, proteomics study on (i) whole milk whey and (ii) extracellular vesicle (EV) enriched milk whey samples, from day 21 of pregnancy and day 21 of the oestrous cycle, in order to identify potential protein biomarkers of early pregnancy. The oestrous cycles of 10 dairy cows were synchronised, they went through one (control) oestrous cycle and these cows were artificially inseminated during the following oestrous. These cows were confirmed pregnant by ultrasound scanning. Milk whey samples were collected on day 21 of the oestrous cycle and on day 21 post AI. A Q-Exactive was used to analyse whole milk whey samples and EV enriched milk whey samples by LC-MS/MS and subsequent analyses of the label-free quantitative data was performed in MaxQuant and Perseus. Four proteins (APOB, SPADH1, PLIN2 and LPO) were differentially expressed between the proteomes of whole milk whey from day 21 of pregnancy and day 21 of the oestrous cycle (P<0.05). Ten proteins (PIGR, PGD, QSOX1, MUC1, SRPRA, MD2, GAPDH, FOLR1, GPRC5B and HHIPL2) were differentially expressed between the proteomes of milk whey from day 21 of pregnancy and day 21 of the oestrous cycle (P<0.05). These proteins are potential milk whey biomarkers of early pregnancy; however, the small fold change differences in their abundance between samples obtained during early pregnancy and during oestrous will restrict their use in a pregnancy diagnosis test.
2018-04-23 | PXD007927 | Pride
Project description:Interventions: Standard of care anticancer treatment plus enoxaparin thromboprophylaxis 40mg self-administered subcutaneously once daily for minimum 3 months, or until completion of anticancer therapy, to maximum 6 months (adherence monitored by drug returns).
Primary outcome(s): Objectively confirmed symptomatic or asymptomatic thromboembolism.
All thromboembolic events must be confirmed by appropriate standard diagnostic investigations such as radiological imaging for DVT or PE and cardiac investigations for suspected myocardial infarct. Study specific imaging will not be performed. A blinded clinical review panel will directly assess and review all radiological and cardiac investigations to confirm events. [At time of any routine imagining for cancer response or at clinical suspicion of thromboembolism, until six months after randomisation.
]
Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Safety/efficacy
| 2467213 | ecrin-mdr-crc
Project description:Protein abundance in Rosette leafs at start of day (2h light)
2009-12-01 | PRD000141 | Pride
Project description:Maternal whole blood colected longitudinally were profiled using Affymetrix Human Transcriptome Arrays . This is a re-analysis of GSE121974, with additional metadata and different summarization of gene expression at ENTREZ ID level instead of Transcript Cluster as in the original submission. LMP is the date at the last menstrual period. Oper_LMP is the date at the last menstrual period with eventual adjustment based on ultrasound determination. Gestational age (GA) (weeks) is defined as (Date at sample - Oper_LMP)/7. For control pregnancies, SubGroup defines those with spontaneous labor at term (TL) as opposed with those delivered by cesarean section (TNL). Train is 1 if the sample was used in sub-challenge 1 in the training set as opposed to test set (0). D2 is 1 if the sample was used in the 2 interval prediction scenario, and if yes, it was assigned to the interval given by column D2Interval. D3 is 1 if the sample was used in the 3 interval prediction scenario, and if yes, it was assigned to the interval given by column D3Interval. DiagnosisGA is the gestational age at diagnosis with any disease indicated by the Group variable, and it is set to NA for normal pregnancies.
2021-05-24 | GSE149436 | GEO